Home > Oncology > BCC 2019 > Special Lectures > What Is the Clinical Benefit of Treatment of Patients with Early Breast Cancer?

What Is the Clinical Benefit of Treatment of Patients with Early Breast Cancer?

Presented By
Prof. Ann Partridge, Dana-Farber Cancer Institute, Boston, USA
Conference
BCC 2019

Prof. Ann Partridge (Dana-Farber Cancer Institute, Boston, USA) addressed the relevance of clinical benefit, clinical meaningfulness, and shared decision-making in the treatment of patients with early breast cancer.

Due to improvements in local and systemic treatments, the age-adjusted breast cancer mortality rate has gradually dropped in the last decades: from about 70 per 100,000 women (40-84 years) in the 1970’s to <40 per 100,000 women now. In light of the improved outcomes of the treatment, the definition of clinical benefit of a treatment has also evolved, Partridge said. In the 1970’s, clinical benefit meant that a patient had an objective response to the treatment. In the 1980’s, overall survival, quality of life, and physical functioning became objective parameters to define benefit. Since the 1990’s, the definition is mainly related to surrogate parameters like progression-free survival, overall response rates, durability of responses (in part...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on